Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era
Publication
, Conference
Clark, JI; Wong, MK; Daniels, GA; Kaufman, HL; McDermott, DF; Morse, MA; Aung, S
Published in: BJU INTERNATIONAL
October 1, 2014
Duke Scholars
Published In
BJU INTERNATIONAL
EISSN
1464-410X
ISSN
1464-4096
Publication Date
October 1, 2014
Volume
114
Start / End Page
5 / 5
Location
Chicago, IL
Publisher
WILEY-BLACKWELL
Conference Name
13th International Kidney Cancer Symposium
Related Subject Headings
- Urology & Nephrology
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Clark, J. I., Wong, M. K., Daniels, G. A., Kaufman, H. L., McDermott, D. F., Morse, M. A., & Aung, S. (2014). Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era. In BJU INTERNATIONAL (Vol. 114, pp. 5–5). Chicago, IL: WILEY-BLACKWELL.
Clark, Joseph I., Michael K. Wong, Gregory A. Daniels, Howard L. Kaufman, David F. McDermott, Michael A. Morse, and Sandra Aung. “Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era.” In BJU INTERNATIONAL, 114:5–5. WILEY-BLACKWELL, 2014.
Clark JI, Wong MK, Daniels GA, Kaufman HL, McDermott DF, Morse MA, et al. Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era. In: BJU INTERNATIONAL. WILEY-BLACKWELL; 2014. p. 5–5.
Clark, Joseph I., et al. “Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era.” BJU INTERNATIONAL, vol. 114, WILEY-BLACKWELL, 2014, pp. 5–5.
Clark JI, Wong MK, Daniels GA, Kaufman HL, McDermott DF, Morse MA, Aung S. Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era. BJU INTERNATIONAL. WILEY-BLACKWELL; 2014. p. 5–5.
Published In
BJU INTERNATIONAL
EISSN
1464-410X
ISSN
1464-4096
Publication Date
October 1, 2014
Volume
114
Start / End Page
5 / 5
Location
Chicago, IL
Publisher
WILEY-BLACKWELL
Conference Name
13th International Kidney Cancer Symposium
Related Subject Headings
- Urology & Nephrology
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1103 Clinical Sciences